Here, we show that among NSCLC patients treated with targeted therapies or immunotherapy, there is a significant incongruence in receiving a molecular diagnostic test and receiving its associated treatment, as almost half of all treated patients did not receive any prerequisite testing to assess eligibility, with upwards of 60% of patients treated with EGFR inhibitors, specifically, being untested for the EGFR mutation prior to treatment. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.